Darryl Sleep on Collaboration and Partnership Across the Entire HHT Community: Patients Can’t Wait!
Darryl Sleep, Former Head Global Public Health at Amgen, BioPharma Executive, reposted from Azmi Nabulsi on LinkedIn:
”I am honored to be part of a dedicated team committed to developing focused, targeted therapeutics to address significant unmet medical need patients living with HHT.
The collaboration and partnership across the entire HHT community of researchers, academics, patient advocacy, patients and caregivers is truly inspiring.
All stakeholders work together with urgency and a deep commitment to improve the lives patients living with HHT.
Patients can’t wait!”
Quoting Azmi Nabulsi‘s post:
”It’s a proud moment for our team to see the engasertib data published in The New England Journal of Medicine.
This recognition validates the strength of the science, the rigor behind the work, and the potential impact for the HHT community.
Thank you to our team, our investigators, and the patients who made this possible.
We now move into the next phase with clarity and confidence as we advance toward our Phase 3 study in 2026.”
Stay updated with Hemostasis Today.
-
Sep 4, 2026, 11:18Aanika Roshni: When Blood, Biology, and Mechanics Intersect
-
Sep 4, 2026, 10:01Ifeanyichukwu Ifechidere: Making Coagulation Simpler and More Practical
-
Sep 4, 2026, 09:49Omid Khalafi: When the ‘Rules of Three’ Break – What Is Really Happening?
-
Sep 4, 2026, 09:27Hilly Paige: What ESC 2026 Taught Us About LDL-C Management
-
Sep 4, 2026, 05:38Faizan Khan: Why Common Exposures Matter in VTE Risk
-
Sep 4, 2026, 04:56Marwa Mostafa: Microcytosis Is Not Always Iron Deficiency
-
Sep 4, 2026, 03:18Mukesh Kumar Maurya: Beyond ‘aPL Thrombosis’ – A Modern Approach to APS
-
Sep 4, 2026, 02:44Ahmed Kotb: Emergency Management of Critical Bleeding in ITP
-
Sep 4, 2026, 02:30Mario Jimenez: KDIGO 2026 – A More Proactive Approach to IV Iron in Hemodialysis